FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895737382> ?p ?o ?g. }

• W2895737382 endingPage "395" @default.
• W2895737382 startingPage "380" @default.
• W2895737382 abstract "Licensure of medical countermeasure vaccines to protect against aerosolized Venezuelan equine encephalitis virus (VEEV) requires the use of the Animal Rule to assess vaccine efficacy, because human studies are not feasible or ethical. We therefore performed a retrospective study of VEE cases that occurred in at-risk laboratory workers and support personnel during the United States Biowarfare Program (1943-1969) to better define percutaneous- and aerosol-acquired VEE in humans and to compare these results with those described for the NHP model (in which high-dose aerosol VEEV challenge led to more severe encephalitis than parenteral challenge). Record review and analysis of 17 aerosol- and 23 percutaneous-acquired human cases of VEE included incubation period, symptoms, physical examination findings, and markers of infection. Human VEE disease by both exposure routes presented as acute febrile illness, typically with fever, chills, headache, back pain, malaise, myalgia, anorexia, and nausea. Aerosol exposure more commonly led to upper respiratory tract-associated findings of sore throat (59% compared with 26%), pharyngeal erythema (76% compared with 52%), neck pain (29% compared with 4%), and cervical lymphadenopathy (29% compared with 4%). Other disease manifestations, including encephalitis, were similar between the 2 exposure groups. The increase in upper respiratory tract findings in aerosol-acquired VEE in humans has not previously been reported but is supported by the mouse model, which showed nasal mucosal necrosis, necrotizing rhinitis, and an increase in upper respiratory tract viral burden associated with aerosol VEEV challenge. Fever, viremia, and lymphopenia were common markers of VEE disease in both humans and NHP, regardless of the exposure route. Taken collectively, our findings provide support for use of the nonlethal NHP model for advanced development of medical countermeasures against aerosol- or percutaneous-acquired VEE." @default.
• W2895737382 created "2018-10-12" @default.
• W2895737382 creator A5023512052 @default.
• W2895737382 creator A5030862738 @default.
• W2895737382 creator A5043513366 @default.
• W2895737382 creator A5064503164 @default.
• W2895737382 creator A5066047183 @default.
• W2895737382 date "2018-10-01" @default.
• W2895737382 modified "2023-10-05" @default.
• W2895737382 title "Comparison of Aerosol- and Percutaneous-acquired Venezuelan Equine Encephalitis in Humans and Nonhuman Primates for Suitability in Predicting Clinical Efficacy under the Animal Rule" @default.
• W2895737382 cites W1444591420 @default.
• W2895737382 cites W1564531194 @default.
• W2895737382 cites W1710534782 @default.
• W2895737382 cites W1761814004 @default.
• W2895737382 cites W1827404234 @default.
• W2895737382 cites W1853438253 @default.
• W2895737382 cites W1970758220 @default.
• W2895737382 cites W1971726382 @default.
• W2895737382 cites W1981642403 @default.
• W2895737382 cites W1986771053 @default.
• W2895737382 cites W1987987435 @default.
• W2895737382 cites W2001254156 @default.
• W2895737382 cites W2004053206 @default.
• W2895737382 cites W2004924659 @default.
• W2895737382 cites W2022158929 @default.
• W2895737382 cites W2029563272 @default.
• W2895737382 cites W2043177321 @default.
• W2895737382 cites W2043675598 @default.
• W2895737382 cites W2056517678 @default.
• W2895737382 cites W2071630360 @default.
• W2895737382 cites W2072139616 @default.
• W2895737382 cites W2096458204 @default.
• W2895737382 cites W2112441450 @default.
• W2895737382 cites W2113342420 @default.
• W2895737382 cites W2123164501 @default.
• W2895737382 cites W2127787997 @default.
• W2895737382 cites W2129308288 @default.
• W2895737382 cites W2132909636 @default.
• W2895737382 cites W2149876127 @default.
• W2895737382 cites W2174172237 @default.
• W2895737382 cites W2195173326 @default.
• W2895737382 cites W2227599680 @default.
• W2895737382 cites W2312527009 @default.
• W2895737382 cites W2326512172 @default.
• W2895737382 cites W2402331591 @default.
• W2895737382 cites W2404135330 @default.
• W2895737382 cites W2408647347 @default.
• W2895737382 cites W2409687612 @default.
• W2895737382 cites W2411368730 @default.
• W2895737382 cites W2414090874 @default.
• W2895737382 cites W2415696850 @default.
• W2895737382 cites W2469842141 @default.
• W2895737382 cites W2601086746 @default.
• W2895737382 cites W360632296 @default.
• W2895737382 cites W86180392 @default.
• W2895737382 doi "https://doi.org/10.30802/aalas-cm-18-000027" @default.
• W2895737382 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6200028" @default.
• W2895737382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30282570" @default.
• W2895737382 hasPublicationYear "2018" @default.
• W2895737382 type Work @default.
• W2895737382 sameAs 2895737382 @default.
• W2895737382 citedByCount "16" @default.
• W2895737382 countsByYear W28957373822019 @default.
• W2895737382 countsByYear W28957373822020 @default.
• W2895737382 countsByYear W28957373822021 @default.
• W2895737382 countsByYear W28957373822022 @default.
• W2895737382 countsByYear W28957373822023 @default.
• W2895737382 crossrefType "journal-article" @default.
• W2895737382 hasAuthorship W2895737382A5023512052 @default.
• W2895737382 hasAuthorship W2895737382A5030862738 @default.
• W2895737382 hasAuthorship W2895737382A5043513366 @default.
• W2895737382 hasAuthorship W2895737382A5064503164 @default.
• W2895737382 hasAuthorship W2895737382A5066047183 @default.
• W2895737382 hasBestOaLocation W28957373822 @default.
• W2895737382 hasConcept C126322002 @default.
• W2895737382 hasConcept C203014093 @default.
• W2895737382 hasConcept C2522874641 @default.
• W2895737382 hasConcept C2777062976 @default.
• W2895737382 hasConcept C2777870961 @default.
• W2895737382 hasConcept C2778594517 @default.
• W2895737382 hasConcept C2778616394 @default.
• W2895737382 hasConcept C2779277585 @default.
• W2895737382 hasConcept C71924100 @default.
• W2895737382 hasConcept C83455156 @default.
• W2895737382 hasConceptScore W2895737382C126322002 @default.
• W2895737382 hasConceptScore W2895737382C203014093 @default.
• W2895737382 hasConceptScore W2895737382C2522874641 @default.
• W2895737382 hasConceptScore W2895737382C2777062976 @default.
• W2895737382 hasConceptScore W2895737382C2777870961 @default.
• W2895737382 hasConceptScore W2895737382C2778594517 @default.
• W2895737382 hasConceptScore W2895737382C2778616394 @default.
• W2895737382 hasConceptScore W2895737382C2779277585 @default.
• W2895737382 hasConceptScore W2895737382C71924100 @default.
• W2895737382 hasConceptScore W2895737382C83455156 @default.
• W2895737382 hasIssue "5" @default.
• W2895737382 hasLocation W28957373821 @default.
• W2895737382 hasLocation W28957373822 @default.
• W2895737382 hasLocation W28957373823 @default.

• next